A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary…
Overview of attention for article published in Gynecologic Oncology, July 2017
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (80th percentile)
-
Good Attention Score compared to outputs of the same age and source (74th percentile)
Readers on
- mendeley
- 100 Mendeley